Testing autoantibody reduction for progressive IPF
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a treatment to reduce certain antibodies in the blood that may be making your idiopathic pulmonary fibrosis (IPF) worse. The goal is to slow down the progression of the disease and help you breathe easier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 85 years old.
- You have been diagnosed with idiopathic pulmonary fibrosis (IPF) and it has been getting worse in the last year, as shown by a significant drop in your lung function.
- You have not had IPF for more than 10 years from when it was first diagnosed.
- You are up to date on your COVID-19 vaccines, specifically the 2025-2026 version, and received it 1 to 26 weeks before starting the trial.
- You are not currently taking high doses of steroids or certain immune-suppressing medications like rituximab in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called MTX-463 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if targeting a protein called WISP1 can slow lung scarring and help you breathe better.
This trial tests whether giving a medication called intravenous immunoglobulin (IVIG) can help people with IPF who are hospitalized for a sudden worsening of their lung condition. The treatment aims to reduce inflammation and improve recovery.
This trial tests an oral medicine called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. It aims to see if the drug can help slow the disease. You may qualify if you are 40 or older, have a confirmed IPF diagnosis with certain lung function levels, and are either on a stable dose of standard IPF meds or not taking them.
This study uses detailed CT scans to find better ways to treat idiopathic pulmonary fibrosis (IPF). It may help doctors choose the right treatment for each person.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.